Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. The company aims to integrate traditional biology research with advanced engineering to develop medicines more efficiently. Its initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. The company believes its product candidates have strong scientific and clinical potential to become critical medicines in various cancer treatments. Eikon Therapeutics' strategy involves deploying its technology platform, including its proprietary single molecule tracking (SMT) system, to develop internally-derived novel therapies. It also leverages the expertise of its management team to opportunistically in-license promising assets. The company's most advanced product candidate is EIK1001, a toll-like receptor (TLR) 7/8 dual-agonist. EIK1001 is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. The company is led by Dr. Roger M. Perlmutter, M.D., Ph.D., its Chair and Chief Executive Officer, and Dr. Roy Baynes, M.D., Ph.D., its Chief Medical Officer.